128 related articles for article (PubMed ID: 28906258)
1. Early tumor shrinkage indicates a favorable response to bevacizumab-based first-line chemotherapy for metastatic colorectal cancer.
Ito M; Kusaba H; Mukaide S; Kishimoto J; Shimokawa H; Tamura S; Makiyama A; Hirano G; Oda H; Shirakawa T; Komoda M; Uchino K; Tanaka R; Mitsugi K; Esaki T; Arita S; Ariyama H; Akashi K; Baba E
Anticancer Drugs; 2017 Nov; 28(10):1166-1173. PubMed ID: 28906258
[TBL] [Abstract][Full Text] [Related]
2. Clinical impact of primary tumour location, early tumour shrinkage, and depth of response in the treatment of metastatic colorectal cancer with first-line chemotherapy plus cetuximab or bevacizumab.
Sagawa T; Sato Y; Hirakawa M; Hamaguchi K; Fukuya A; Okamoto K; Miyamoto H; Muguruma N; Fujikawa K; Takahashi Y; Takayama T
Sci Rep; 2020 Nov; 10(1):19815. PubMed ID: 33188279
[TBL] [Abstract][Full Text] [Related]
3. Early Tumor Shrinkage and Depth of Response as Predictors of Favorable Treatment Outcomes in Patients with Metastatic Colorectal Cancer Treated with FOLFOX Plus Cetuximab (JACCRO CC-05).
Tsuji A; Sunakawa Y; Ichikawa W; Nakamura M; Kochi M; Denda T; Yamaguchi T; Shimada K; Takagane A; Tani S; Kotaka M; Kuramochi H; Furushima K; Koike J; Yonemura Y; Takeuchi M; Fujii M; Nakajima T
Target Oncol; 2016 Dec; 11(6):799-806. PubMed ID: 27306648
[TBL] [Abstract][Full Text] [Related]
4. Impact of Size and Location of Metastases on Early Tumor Shrinkage and Depth of Response in Patients With Metastatic Colorectal Cancer: Subgroup Findings of the Randomized, Open-Label Phase 3 Trial FIRE-3/AIO KRK-0306.
Froelich MF; Petersen EL; Heinemann V; Nörenberg D; Hesse N; Gesenhues AB; Modest DP; Sommer WH; Hofmann FO; Stintzing S; Holch JW
Clin Colorectal Cancer; 2020 Dec; 19(4):291-300.e5. PubMed ID: 32917529
[TBL] [Abstract][Full Text] [Related]
5. 'Deepness of Response' Is Associated with Overall Survival in Standard Systemic Chemotherapy for Metastatic Colorectal Cancer.
Nozawa H; Nishikawa T; Tanaka T; Tanaka J; Kiyomatsu T; Kawai K; Hata K; Kazama S; Yamaguchi H; Ishihara S; Sunami E; Kitayama J; Watanabe T
Chemotherapy; 2014; 60(5-6):360-7. PubMed ID: 26389969
[TBL] [Abstract][Full Text] [Related]
6. Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab.
Mazard T; Boonsirikamchai P; Overman MJ; Asran MA; Choi H; Herron D; Eng C; Maru DM; Ychou M; Vauthey JN; Loyer EM; Kopetz S
Gut; 2018 Jun; 67(6):1095-1102. PubMed ID: 29084828
[TBL] [Abstract][Full Text] [Related]
7. Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC).
Heinemann V; Stintzing S; Modest DP; Giessen-Jung C; Michl M; Mansmann UR
Eur J Cancer; 2015 Sep; 51(14):1927-36. PubMed ID: 26188850
[TBL] [Abstract][Full Text] [Related]
8. Clinical Relevance of Alternative Endpoints in Colorectal Cancer First-Line Therapy With Bevacizumab: A Retrospective Study.
Turpin A; Paget-Bailly S; Ploquin A; Hollebecque A; Peugniez C; El-Hajbi F; Bonnetain F; Hebbar M
Clin Colorectal Cancer; 2018 Mar; 17(1):e99-e107. PubMed ID: 29128267
[TBL] [Abstract][Full Text] [Related]
9. Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306).
Modest DP; Stintzing S; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Scheithauer W; Kirchner T; Jung A; Stauch M; von Einem JC; Moehler M; Held S; Heinemann V;
Int J Cancer; 2017 Apr; 140(8):1918-1925. PubMed ID: 28032641
[TBL] [Abstract][Full Text] [Related]
10. Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy-Analysis of the Phase 3 XELAVIRI Trial.
Kurreck A; Heinemann V; Fischer von Weikersthal L; Decker T; Kaiser F; Uhlig J; Schenk M; Freiberg-Richter J; Peuser B; Denzlinger C; Graeven U; Heinrich K; Held S; Stahler A; Alig AHS; Jelas I; von Einem JC; Stintzing S; Giessen-Jung C; Modest DP
Front Oncol; 2022; 12():751453. PubMed ID: 35251955
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer.
Bazarbashi S; Aljubran A; Alzahrani A; Mohieldin A; Soudy H; Shoukri M
Cancer Med; 2015 Oct; 4(10):1505-13. PubMed ID: 26207614
[TBL] [Abstract][Full Text] [Related]
12. Texture features of colorectal liver metastases on pretreatment contrast-enhanced CT may predict response and prognosis in patients treated with bevacizumab-containing chemotherapy: a pilot study including comparison with standard chemotherapy.
Ravanelli M; Agazzi GM; Tononcelli E; Roca E; Cabassa P; Baiocchi G; Berruti A; Maroldi R; Farina D
Radiol Med; 2019 Sep; 124(9):877-886. PubMed ID: 31172448
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Impact of Neutrophil/Lymphocyte Ratio, Platelet Count, CRP, and Albumin Levels in Metastatic Colorectal Cancer Patients Treated with FOLFIRI-Bevacizumab.
Artaç M; Uysal M; Karaağaç M; Korkmaz L; Er Z; Güler T; Börüban MC; Bozcuk H
J Gastrointest Cancer; 2017 Jun; 48(2):176-180. PubMed ID: 27714653
[TBL] [Abstract][Full Text] [Related]
14. Quantitative evaluation of liver metastases density on computed tomography: A new tool to evaluate early response to bevacizumab-containing chemotherapy.
Mazard T; Assenat E; Dupuy M; Mollevi C; René A; Adenis A; Chauffert B; Boucher E; Francois E; Pierga JY; Ducreux M; Ychou M; Gallix B
Dig Liver Dis; 2019 Aug; 51(8):1185-1191. PubMed ID: 31085108
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of First-Line Bevacizumab in Metastatic Colorectal Cancer: The Observational Cohort Study GRETA.
Franchi M; Barni S; Tagliabue G; Ricci P; Mazzucco W; Tumino R; Caputo A; Corrao G;
Oncologist; 2019 Mar; 24(3):358-365. PubMed ID: 30097524
[TBL] [Abstract][Full Text] [Related]
16. Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab.
Lee CK; Kim SS; Park S; Kim C; Heo SJ; Lim JS; Kim H; Kim HS; Rha SY; Chung HC; Park S; Jung M
Oncotarget; 2017 May; 8(19):31169-31179. PubMed ID: 28415714
[TBL] [Abstract][Full Text] [Related]
17. Comparison of computed tomography imaging analyses for evaluation after chemotherapy in patients with colorectal cancer: a retrospective pooled analysis of six phase II clinical trials.
Hirose K; Oki E; Shimose T; Sakamoto S; Sasaki S; Jogo T; Hu Q; Tsuda Y; Ando K; Nakashima Y; Saeki H; Mori M
Int J Clin Oncol; 2019 Nov; 24(11):1397-1405. PubMed ID: 31332611
[TBL] [Abstract][Full Text] [Related]
18. CEA Response and Depth of Response (DpR) to Predict Clinical Outcomes of First-Line Cetuximab Treatment for Metastatic Colorectal Cancer.
Sunakawa Y; Tsuji A; Denda T; Segawa Y; Negoro Y; Shimada K; Kochi M; Nakamura M; Kotaka M; Tanioka H; Takagane A; Tani S; Yamaguchi T; Watanabe T; Takeuchi M; Fujii M; Ichikawa W
Target Oncol; 2017 Dec; 12(6):787-794. PubMed ID: 29064002
[TBL] [Abstract][Full Text] [Related]
19. Assessing prognostic value of early tumor shrinkage and depth of response in first-line therapy for patients with advanced unresectable pancreatic cancer.
Yang X; Xian X; Wang Y; Qiu M
BMC Gastroenterol; 2021 Jul; 21(1):294. PubMed ID: 34266410
[TBL] [Abstract][Full Text] [Related]
20. Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study.
Stintzing S; Miller-Phillips L; Modest DP; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Held S; Moehler M; Jagenburg A; Kirchner T; Jung A; Heinemann V;
Eur J Cancer; 2017 Jul; 79():50-60. PubMed ID: 28463756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
